Candel Therapeutics Files 8-K Report
Ticker: CADL · Form: 8-K · Filed: May 28, 2025 · CIK: 1841387
Sentiment: neutral
Topics: 8-K, SEC Filing, Financials
TL;DR
Candel Therapeutics filed an 8-K, likely with financial updates.
AI Summary
On May 28, 2025, Candel Therapeutics, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, along with other events and a Regulation FD disclosure. No specific financial figures or new material events were detailed in the provided excerpt.
Why It Matters
This 8-K filing indicates Candel Therapeutics is providing updated information to the SEC, which could include financial details or other material events relevant to investors.
Risk Assessment
Risk Level: low — The filing is a standard 8-K report without immediate indication of significant negative or positive developments.
Key Players & Entities
- Candel Therapeutics, Inc. (company) — Registrant
- May 28, 2025 (date) — Date of earliest event reported
FAQ
What is the primary purpose of this 8-K filing for Candel Therapeutics?
The filing is for a Current Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, indicating it's for material events or updates.
What specific items are being reported in this 8-K?
The filing includes information on Regulation FD Disclosure, Other Events, and Financial Statements and Exhibits.
When was the earliest event reported in this filing?
The earliest event reported was on May 28, 2025.
What is Candel Therapeutics' principal executive office address?
The address is 117 Kendrick St Suite 450, Needham, Massachusetts 02494.
What is Candel Therapeutics' telephone number?
The telephone number is (617) 916-5445.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on May 28, 2025 regarding Candel Therapeutics, Inc. (CADL).